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INTRODUCTION
The risk factors for hepatic carcinogenesis in patients with 
chronic hepatitis have been extensively studied(1) and liver fibrosis 
is known to be the most significant factor involved. Treatment 
decisions are based, in part, on the stage of liver fibrosis, which 
marks the progression to cirrhosis. The Metavir score is very useful 
scale to gauge the fibrosis severity. 
The gold standard for determining the extent of fibrosis is liver 
biopsy(2). However, this procedure carries a moderate risk for com-
plications such as bleeding and a small risk of death(2,3). Then there 
is interest in the development of non-invasive testing to determine 
the degree of hepatic fibrosis.
Bioimpedance is an electrical property of living tissues that has 
been applied in many biomedical settings, such as the quantification 
of brain edema in neurosurgery(4) differentiating between cancerous 
pulmonary masses and pulmonary masses due to pneumonia(5), in 
in prostate cancer(6). However, bipolar bioimpedance has, so far as 
we are aware, not previously been applied in assessing liver fibrosis. 
Bioimpedance uses a weak direct current (DC), voltage 1.28 V 
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ABSTRACT – Background – Fibrosis are common structural hepatic change in patients with chronic hepatitis. Liver biopsy is the gold standard for de-
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applied for two minutes and in bipolar mode. In living tissues, elec-
trical current is normally limited in living tissue by highly insulating 
cell membranes, although measurements of this current can reflect 
acid levels in tissues and can therefore be used to detect hepatic 
alterations provoked by viral infection or abnormal architecture 
resulting from tissue fibrosis. Moreover, electrical current can be 
impeded differently, which enables the detection of  differences 
between normal and fibrotic tissue. 
The aim of this research was to assess the accuracy of non-in-
vasive bipolar bioimpedance technology for the detection of liver 
fibrosis using physiological data intra and inter groups of  the 
healthy and chronic viral hepatitis C patients
METHODS
This is a prospective study between January and December 
2014. To assess the level of liver fibrosis comparing bipolar bio-
impedance data from a Group 1 Control of healthy individuals, not 
biopsied, with the data and histopathology results of the Group 
2 Positive patients with chronic hepatitis (virus C positive), biop-
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sied and subdivided according to Metavir score into Sub Group 
2A (F0-F1) patients without or with minimal portal fibrosis and 
Sub Group 2B (F3-F4),patients with numerous septa/cirrhosis. 
Approval number of the Ethical Committee – Faculty of Medical 
Science of Campinas (Unicamp) is CEP 542/2010. 
As estimated by the sample calculation with significance level 
of 5% with 80% power, this study included 60 patients with chronic 
hepatitis, of both sexes that had all previously signed consent form 
and had positive serology for hepatitis C virus (anti-HCV positive). 
These exams were performed by health centers from cities within 
the greater metropolitan area of Campinas, São Paulo state, south-
east of Brazil, whose patients were referred to Gastrocentro, State 
University of Campinas – Unicamp, for biopsies to be carried out 
in order to determine the stage of hepatitis virus C.
A Group 1 Control composed of 50 healthy patients, aged 18 
to 57years, who were without symptoms, and who were not under-
going any treatments or liver biopsies and had negative lab tests 
for chronic hepatitis (virus C) were included only for the purpose 
of comparing bioelectric data.
Patients were excluded for the following reasons: 1) if they had a 
neurological disorder precluding the ability to sign a consent form; 
2) if  they had any constraints to use the bipolar bioimpedance, that 
such as presence of an external defibrillator, skin lesions likely to 
come into contact with the electrodes, excessive perspiration, car-
diac pacemaker, electronic life support, any implanted electronic 
device, metallic pins or prostheses in digits or joints, pregnancy 
from the third trimester onwards, and absence of a limb; 3) if  the 
Metavir fibrosis score is F2 only in specific analysis of liver fibrosis 
in the Group 2 Positive (chronic hepatitis group).
Bipolar bioimpedance measurements, were performed in all 
one hundred and ten patients of an average age of 39 (20–64), 57 
men and 53 women, using the Electro Interstitial Scan-Galvanic 
Skin (EIS-GS) bioimpedance module with DC current, which uses 
the ES Complex (Electro Sensor Complex) system medical device 
(LD Technology Ltd, USA).(7)
The chronic hepatitis group immediately prior to the liver 
biopsy underwent a “blind” examination with electrical bioimped-
ance using a weak direct current (DC current), voltage 128 V 
which was applied for two minutes in bipolar mode performing 
measures of  the electrical conductivity of  different pathways in 
the body. 
The parameter analyzed in the EIS-GS module was the delta of 
the electrical resistance values for the pathway value for the left foot to 
right hand (anode to cathode) minus the pathway value for the right 
hand to left foot (cathode to anode). The conductance measurement 
values are displayed in a scale from 0 to 100 for each pathway.
EIS and electrical conductance/chronoamperometry
With direct current, the plasma membrane acts as an insulator, 
and the current is therefore not able to penetrate the cell. Thus, 
most of the current flows around the cell in the interstitial fluid(8) 
The analysis of the direct current at the cathode and anode in an 
electrolytic solution is performed at both the anode and cathode. 
For the analysis at the cathode, the electrochemical reaction is 
represented by the following:
2H2O + 2
e= H2 (gas) + 2 OH
-(base)
For the analysis at the anode, the electrochemical reaction for 
water is represented by the following: 
2H2O = O2 (gas) + 4H+   + 4
e- (acid)
Using as normal references the conductance values 9.2 µS 
(-4/19) of  the Group 1 Control, was compared the groups 1 and 
2 to determine the specificity and sensitivity of  the bipolar bio-
impedance data (delta of  conductance) to detect liver fibrosis. 
The fibrosis severity was analyzed comparing the Sub Groups 2A 
and 2B. ES Complex Algorithm was made by Statistical Neural 
Network version 10. A part of  developed algorithm was made 
in «C» language.
This was a triple blind study since the bioimpedance examina-
tion was done immediately before the liver biopsy without knowing 
the results. The liver biopsy was also performed without knowing 
the result of  bioimpedance and liver fibrosis was graded by an 
independent pathologist using the Metavir classification did not 
know the result of bioimpedance.
RESULTS
Demographic data can be seen in TABLE 1. From the com-
parison between Groups 1 and 2: 
TABLE 1. Demographic data for the 4 study groups: Group 1 Control, Group 2 Positive for hepatitis C virus-infected patients, Sub Group 2A-Metavir 














N 50 60 25 20
Age 32 (18-57) 46 (28-64) 44 (28-63) 49 (29-64) 0.05
Male/female ratio 0.56 0.66 0.68 0.75 0.05
ALT 15 (12-20) U/L 77 (15-260) U/L 70 (19-260) U/L 83 (15-185) U/L 0.001
AST 26 (15-38) 72 (16-271) 44 (27-78) 75.6 (16-271) 0.001
HCV No 60 25  20 Ns
Delta conductivity 9.2 (-4/19) 1.31 (-6/23) 2.75 (-6/12) 0.62 (-10/23) 0.001
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The delta value for conductance in the pathway representing 
the right foot-left hand minus left hand-right foot demonstrated a 
sensitivity of 85% and a specificity of 78% with a cutoff  value ≤5 
and P=0.0001 (FIGURE 1).
From the comparison between Sub Group 2A (Metavir F0+F1) 
and Sub Group 2B (Metavir F3+F4) the Receiver Operating 
Characteristic curve (ROC curve) neural network for the ES Com-
plex data demonstrated a sensitivity of 85% and a specificity of 
72% with a cutoff  probability >50% and P=0.001 (FIGURE 2). 
The area under the ROC curve (AUROC) is 0.81.
DISCUSSION
Chronic hepatitis is often closely associated with hepatic fibro-
sis. The response to injury consists of  local inflammation followed 
by the recruitment and local proliferation of  myofibroblast-like 
cells and the excessive deposition of  the extracellular matrix. 
Therefore, within the past 20 years, hepatic fibrosis has become 
a common and difficult clinical challenge for gastroenterologists 
worldwide(9).
Progressive degrees of  fibrosis, and ultimately cirrhosis, are 
reflected in alterations in blood levels of various biomarkers, and 
the knowledge of such alterations has led to the development of 
predictive models based on clinically determined algorithms that 
utilize the levels of selected markers(9,10).
One such model, the Hepascore, is based on the serum levels 
of α2-macroglobulin, hyaluronic acid, gammaglutamyltransferase 
(GGT), and total bilirubin in addition to age and sex. In one study, 
a Hepascore ≥0.5 (possible range, 0-1.0) demonstrated a sensitivity 
of  63% and a specificity of  89% for the presence of  significant 
fibrosis (Metavir score ≥F2), whereas a Hepascore <0.5 demon-
strated a sensitivity of 88% and a specificity of 74% for excluding 
a diagnosis of advanced fibrosis(9).
Another useful model is the non-alcoholic fatty liver disease 
(NAFLD) fibrosis score that based on age, hyperglycemia, body 
mass index, platelet count, albumin, and AST/ALT ratio. In the 
validation study demonstrates good accuracy in to predict presence 
or absence of advanced fibrosis with an area under the ROC curve 
of 0.82, sensitivity of 82% and specificity of 88%(11).
Ultrasonic transient elastography or FibroScan (Echosens, 
Paris, France), is a current approach for the non-invasive evaluation 
of liver fibrosis and has been shown to be an accurate predictor 
of  histological fibrosis in patients with chronic hepatitis C. The 
best results with FibroScan is when the patient has higher level of 
fibrosis with AUROC ranging from 0.79 to 0.88 for F > or = 2 and 
0.95 to 0.99 for F=4), and these new trends(12,13).
In the present study, using delta of  the electrical resistance 
values the comparison between patient from the Sub Group 2A 
(Metavir F0+F1) and Sub Group 2B (Metavir F3+F4) demonstrat-
ed good sensitivity (85%) and specificity (72%) to differentiation 
in liver fibrosis severity. The theoretical explanation is that the 
electrical weak DC current used in bipolar bioimpedance can be 
FIGURE 1. Delta value of the conductance. The ROC curve for the Delta 
value of the conductance in the pathway of the right foot-left hand minus 
left hand-right foot for the comparison between Group 1 Control (virus-
negative and within the normal range of ALT/AST levels) and Group 2 
Positive (virus-positive and/or high levels ALT/AST).
FIGURE 2. The neural network. The ROC curve of the neural network for the ES Complex data comparing the Sub Group 2A (Metavir score F0+F1) 
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Positive group:      Diagnostic = 1 60
Negative group:     Diagnostic = 0 50
Disease prevalente (%) 32.4
Area under the ROC curve (AUC) 0.819
Standard Error 0.0570
95% Confidence Interval a 0.712 to 0.899
z statistic 5.594





Ianni Filho D, Boin IFSF, Yamanaka A. 
Bioimpedance: new approach to non-invasive detection of liver fibrosis – a pilot study
Arq Gastroenterol • 2018. v. 55 nº 1 jan/mar • 5
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RESUMO – Contexto – A fibrose é uma alteração hepática estrutural comum em pacientes com hepatite crônica. A biópsia hepática é o padrão ouro para 
determinar a extensão da fibrose hepática. Considerando as dificuldades técnicas e os custos, melhorias em ferramentas de rastreio não-invasivas são 
bastante necessárias. A tecnologia bioimpedância tem se mostrado ser segura para avaliar fibrose tecidual. Objetivo – Avaliar a utilidade do uso da 
bioimpedância bipolar para detectar a severidade da fibrose hepática compatível com a hepatite viral B e C. Métodos – Cento e dez pacientes foram 
estudados, prospectivamente e dois grupos foram formados de acordo com os resultados dos testes laboratoriais para a detecção de HCV, ALT e 
AST: Grupo 1 Controle (n=50 pacientes saudáveis com HCV negativos e com valores de ALT e AST dentro do padrão de normalidade) e Grupo 2 
Positivo (n=60 pacientes positivos para a infecção viral anti-VHC ou HBsAg positiva) que foram biopsiados. Todos os pacientes foram submetidos 
a um exame com o Electro Sensor Complex, que utiliza a bioimpedância bipolar. Para comparar os Grupos 1 e 2, a curva ROC foi utilizada para 
determinar a especificidade e sensibilidade da bioimpedância em detectar a fibrose hepática. Para identificar a severidade da fibrose hepática, o Grupo 
2 Positivo foi subdividido de acordo com os resultados da biópsia (escore Metavir) em: Sub Grupo 2A (F0-F1 n=25 ) – pacientes sem ou com fibrose 
portal mínima e Sub Grupo 2B (F3-F4 n=20) pacientes com numerosos septos/cirrose. A análise estatística foi realizada para analisar as diferenças 
dos valores delta de condutância da bioimpedância. Resultados – A comparação entre os Grupos 1 e 2 mostrou: 1) O valor delta de condutância na 
via do pé direito à mão esquerda menos o valor do delta da mão esquerda ao pé direito demonstrou uma sensibilidade de 85% e uma especificidade 
de 78%, com um valor de corte ≤5 e P=0,0001. 2). Na comparação entre o Sub Grupo 2A (Metavir F0+F1) e o Sub Grupo 2B (Metavir F3 + F4), a 
rede neural para os dados aferidos pelo Electro Sensor Complex demonstrou uma sensibilidade de 85% e uma especificidade de 72%, com um corte 
de probabilidade >50% P=0,001 e AUCROC=0,81. Conclusão – Bioimpedância apresentou boa sensibilidade e aceitável especificidade para a de-
tecção da fibrose hepática utilizando o delta da condutância da bioimpedância. Existe um potencial para o uso da bioimpedância como abordagens 
não-invasivas para o rastreamento da fibrose hepática.
DESCRITORES – Cirrose hepática, diagnóstico. Biópsia. Fibrose. Fígado, patologia. Hepatite C crônica, complicações.
impeded differently, which enables the detection of  differences 
between normal and fibrotic tissue. 
It is not possible to discuss this result with other researchers 
because this is a pioneer study in liver. Prostatic research using 
bioimpedance offers the same explanation to understand how 
it could identify the variation in tissue architecture between dif-
ferent prostatic tissue types. This prompted, Halter RJ(6) and de 
Abreu DS(14,15) to suggest using the electrical properties of the pros-
tate as a means to distinguish cancerous from non-cancerous tissue. 
Bioimpedance is largely a function of a tissue’s cellular mor-
phology and the ionic concentrations of  the tissue’s intra- and 
extra-cellular fluids. Electrical current is normally limited in living 
tissue by highly insulating cell membranes, although measurements 
of this current can reflect acid levels in tissues. The second expla-
nation for why bioimpedance is increased in hepatic fibrosis may 
be related to the fact that fibrotic tissue prevents the flow of the 
current because current flow decreases as resistance increases. A 
decrease in bioimpedance conductivity value (cutoff <5) is inverse-
ly proportional to the electrochemical reaction at the anode and 
can therefore be used to indicate an acidic tissue environment. In 
addition, this acidic tissue environment is likely related to tissue 
damage provoked by HCV infection(7).
Hence, the bipolar bioimpedance used in ES Complex equip-
ment is a tool easy to administer, non-invasive, and has a high 
sensitivity and specificity would be advantageous and a great im-
provement for the screenings to detect liver fibrosis in asymptomatic 
chronic hepatitis C virus infection but not for primary diagnostic 
use. The value of such a tool would increase if  non-clinical per-
sonnel, who assist the doctors, could also use it.
This study has certain limitations, such as the sample size and 
the exclusion of 19 patients with positive Metavir score F2 (portal 
fibrosis with few septa) although one of the challenges of the liver 
fibrosis evaluation method is to identify the Metavir F2. 
But the purpose of  this pilot study that could not draw con-
clusive results since it is not a validation study. The intention 
is to present preliminary findings and to evaluate the potential 
of  the use of  bioimpedance as a supporting parameter that in 
the future can be included to the currently methods of  the liver 
fibrosis identification may be to increase yours theirs sensitivity 
and specificity. Thus, bioimpedance further studies with a larger 
patient population and the use of  multifrequential tetrapolar 
bioimpedance may provide more information not only on the 
interstitium but also on the intracellular environment thus con-
tributed to the increased accuracy of  the clinicians detect chronic 
liver fibrosis during screening procedures.
CONCLUSION
The bioimpedance demonstrate good to high levels of sensitiv-
ity and specificity to identify structural liver alterations like liver 
fibrosis severity consistent with chronic viral hepatitis C infections 
showing that there is a potential for the use of bioimpedance lie a 
non-invasive technology in the approaches for low-cost and rapid 
screening of liver fibrosis.
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